Foreign-Trade Zone (FTZ) 177, Notification of Proposed Production Activity; AstraZeneca Pharmaceuticals LP (Pharmaceutical Products); Mount Vernon, Indiana

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

April 3, 2025

Issuing agencies

Commerce DepartmentForeign-Trade Zones Board

Full Text

<html>
<head>
<title>Federal Register, Volume 90 Issue 63 (Thursday, April 3, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 63 (Thursday, April 3, 2025)]
[Notices]
[Page 14599]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-05743]


========================================================================
Notices
                                                Federal Register
________________________________________________________________________

This section of the FEDERAL REGISTER contains documents other than rules 
or proposed rules that are applicable to the public. Notices of hearings 
and investigations, committee meetings, agency decisions and rulings, 
delegations of authority, filing of petitions and applications and agency 
statements of organization and functions are examples of documents 
appearing in this section.

========================================================================


Federal Register / Vol. 90, No. 63 / Thursday, April 3, 2025 / 
Notices

[[Page 14599]]



DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-19-2025]


Foreign-Trade Zone (FTZ) 177, Notification of Proposed Production 
Activity; AstraZeneca Pharmaceuticals LP (Pharmaceutical Products); 
Mount Vernon, Indiana

    AstraZeneca Pharmaceuticals LP submitted a notification of proposed 
production activity to the FTZ Board (the Board) for its facilities in 
Mount Vernon, Indiana within Subzone 177A. The notification conforming 
to the requirements of the Board's regulations (15 CFR 400.22) was 
received on March 27, 2025.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material(s)/component(s) and 
specific finished product(s) described in the submitted notification 
(summarized below) and subsequently authorized by the Board. The 
benefits that may stem from conducting production activity under FTZ 
procedures are explained in the background section of the Board's 
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished 
product and material/component would be added to the production 
authority that the Board previously approved for the operation, as 
reflected on the Board's website.
    The proposed finished product is zibotentan/dapagliflozin tablets 
(duty-free).
    The proposed foreign-status material/component is zibotentan active 
pharmaceutical ingredient (duty rate--6.5%). The request indicates that 
the material/component is subject to duties under section 1702(a)(1)(B) 
of the International Emergency Economic Powers Act (section 1702), 
depending on the country of origin. The applicable section 1702 
decisions require subject merchandise to be admitted to FTZs in 
privileged foreign status (19 CFR 146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
<a href="/cdn-cgi/l/email-protection#1670626c56626477727338717960"><span class="__cf_email__" data-cfemail="b2d4c6c8f2c6c0d3d6d79cd5ddc4">[email&#160;protected]</span></a>. The closing period for their receipt is May 13, 2025.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Diane Finver at 
<a href="/cdn-cgi/l/email-protection#9fdbf6fef1fab1d9f6f1e9faeddfebedfefbfab1f8f0e9"><span class="__cf_email__" data-cfemail="a8ecc1c9c6cd86eec1c6decddae8dcdac9cccd86cfc7de">[email&#160;protected]</span></a>.

    Dated: March 31, 2025.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2025-05743 Filed 4-2-25; 8:45 am]
BILLING CODE 3510-DS-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on April 3, 2025.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.